Avalyn Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Avalyn Pharmaceuticals's estimated annual revenue is currently $5.4M per year.
- Avalyn Pharmaceuticals's estimated revenue per employee is $155,000
Employee Data
- Avalyn Pharmaceuticals has 35 Employees.
- Avalyn Pharmaceuticals grew their employee count by 25% last year.
Avalyn Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | SVP, Business Operations | Reveal Email/Phone |
3 | SVP | Reveal Email/Phone |
4 | SVP, Clinical Development Operations | Reveal Email/Phone |
5 | SVP, Product Development | Reveal Email/Phone |
6 | Sr VP | Reveal Email/Phone |
7 | SVP, Finance & Administration | Reveal Email/Phone |
8 | SVP, Business Operations | Reveal Email/Phone |
9 | SVP, Clinical Development | Reveal Email/Phone |
10 | VP Medical Affairs | Reveal Email/Phone |
Avalyn Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Avalyn Pharmaceuticals?
N/A
Total Funding
35
Number of Employees
$5.4M
Revenue (est)
25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Avalyn Pharmaceuticals News
2022-04-06 - BioWorld MedTech Patent Highlights: Week 13
For prior patenting published Avalyn Pharma's former name (Genoa Pharmaceuticals) in which one of the inventors (Surber) described...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4.1M | 35 | 9% | N/A |
#2 | $9.1M | 35 | -8% | N/A |
#3 | $2.9M | 35 | -5% | N/A |
#4 | $6.9M | 35 | 3% | N/A |
#5 | $15M | 35 | 35% | N/A |